Note 14 — Subsequent Events

In accordance with ASC 855, Subsequent Events, the Company has reviewed its operations subsequent to June 30, 2024 to the date these condensed consolidated financial statements were issued, and has determined that, except as set forth below, it does not have any material subsequent events to disclose in these financial statements.

SEC Order

On September 9, 2024, the SEC issued an order against the Company which found that the Company entered into two separation agreements with former employees that each contained language violating Rule 21F-17(a) of the Securities Exchange Act of 1934, as amended. The order imposes a civil money penalty against the Company for the two noted violations in the total amount of $19,500, to be paid in four installments over the course of 360 days from the date of the order and according to the schedule set forth in the order. The first three installments are each in the amount of $5,000. The last installment is in the principal amount of $4,500 and must also contain an amount for interest accrued. The SEC Division of Enforcement may, at any time following the entry of this order, petition the SEC to: (1) reopen this matter to consider whether the Company provided accurate and complete financial information at the time representations in its Form 10-Q for the quarter ended September 30, 2023 were made; and (2) seek an order directing payment of the maximum civil penalty allowable under the law.

Completion of Ceautamed Disposition

As noted above, on October 1, 2024, the 51% owner of First Health elected to exercise the option to purchase the remaining 49% interest in First Health from the Company, effective as of October 2, 2024, paid to the Company the option price of $1.00, and the Company delivered the remaining 49% interest in First Health to such owner.

Additional Equity Transactions

Subsequent to June 30, 2024, an aggregate of 1,527 shares of series B preferred stock were exchanged for debt, which was immediately converted into an aggregate of 258,125 shares of common stock.

Subsequent to June 30, 2024, holders returned an aggregate of 105,670 shares of common stock in exchange for the return of an aggregate of 7,396.77 shares of series C preferred stock. All but 977.98 of those shares of series C preferred stock were then converted into debt and then immediately converted back into an aggregate of 381,934 shares of common stock.

Subsequent to June 30, 2024, the Company issued an aggregate of 4,146,106 shares of common stock upon the conversion of other debt.

Subsequent to June 30, 2024, an aggregate of 54,367 shares of common stock were cancelled by the holders thereof.